A Historic Milestone in the Treatment of Sickle Cell Disease The U.S. Food and Drug Administration (FDA) has given its stamp of approval to the first-ever gene therapies for sickle cell disease (SCD). These therapies, named Casgevy and Lyfgenia, are designed to treat patients aged 12 years and older who have a history of vaso-occlusive… Continue reading FDA Approves Groundbreaking Gene Therapies for Sickle Cell Disease